Published in Dig Dis Sci on December 05, 2008
Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol (2011) 1.55
miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol Cancer (2011) 1.46
Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine. J Transl Med (2011) 1.21
PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice. Br J Cancer (2012) 1.10
Pathogenetic mechanisms in gastric cancer. World J Gastroenterol (2014) 0.97
A functional and transcriptomic analysis of NET1 bioactivity in gastric cancer. BMC Cancer (2011) 0.82
Analysis of cell cycle-related proteins in gastric intramucosal differentiated-type cancers based on mucin phenotypes: a novel hypothesis of early gastric carcinogenesis based on mucin phenotype. BMC Gastroenterol (2010) 0.78
SATB1 overexpression regulates the development and progression in bladder cancer through EMT. PLoS One (2015) 0.77
Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review). Biomed Rep (2013) 0.76
Methylation and Expression of Retinoblastoma and Transforming Growth Factor-β1 Genes in Epstein-Barr Virus-Associated and -Negative Gastric Carcinomas. Gastroenterol Res Pract (2012) 0.75
Increased cyclin T1 expression as a favorable prognostic factor in treating gastric adenocarcinoma. Oncol Lett (2015) 0.75
Poorly Differentiated Medullary Phenotype Predicts Poor Survival in Early Lymph Node-Negative Gastro-Esophageal Adenocarcinomas. PLoS One (2016) 0.75
Cancer cell cycles. Science (1996) 21.29
Cell cycle control and cancer. Science (1994) 10.90
p21/waf1/cip1 in gastric cancer: associations with histopathological subtypes, lymphonodal metastasis, prognosis and p53 status. Scand J Gastroenterol (2001) 1.42
Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res (1997) 1.18
Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol (2000) 1.16
Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol (2003) 1.09
Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer (1997) 1.09
Frequent amplification of the cyclin E gene in human gastric carcinomas. Jpn J Cancer Res (1995) 1.09
Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer (1998) 1.03
Combined evaluation of expressions of cyclin E and p53 proteins as prognostic factors for patients with gastric cancer. Clin Cancer Res (2005) 1.01
Loss of p21WAF1/CIP1 expression correlates with disease progression in gastric carcinoma. Br J Cancer (1997) 0.95
A new prognostic strategy for gastric carcinoma: mRNA expression of tumor growth-related factors in endoscopic biopsy specimens. Ann Surg (1997) 0.90
Expression of cell-cycle regulators, cyclin E and p21WAF1/CIP1, potential prognostic markers for gastric cancer. Eur J Surg Oncol (1999) 0.88
Expression of cell-cycle regulatory proteins cyclin D1, cyclin E, and their inhibitor p21 WAF1/CIP1 in gastric cancer. J Pathol (1999) 0.86
Combined evaluation of expressions of p53 and p21 proteins as prognostic factors for patients with gastric carcinoma. Oncology (2002) 0.86
p21 expression is a prognostic factor in patients with p53-negative gastric cancer. Cancer Lett (2000) 0.85
Expression of cyclin D1 and cyclin E in human gastric carcinoma and its clinicopathologic significance. J Korean Med Sci (1998) 0.85
Loss of p16 and p27 is associated with progression of human gastric cancer. Cancer Lett (2000) 0.85
Expression of cyclin E in human gastric adenomas and adenocarcinomas: correlation with proliferative activity and p53 status. J Exp Ther Oncol (1996) 0.82
Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int J Oncol (2000) 0.82
Expression of p53 and p21waf1/cip1 in gastric carcinoma: lack of inter-relationship or correlation with prognosis. Eur J Surg Oncol (2000) 0.81
Expressions of cyclin E, cyclin dependent kinase 2 and p57(KIP2) in human gastric cancer. Chin Med J (Engl) (2003) 0.81
Immunohistochemical study on the expression of cyclin D1 and E in gastric cancer. Kurume Med J (2000) 0.81
A study on the prognostic value of cyclins D1 and E expression levels in resectable gastric cancer and on some correlations between cyclins expression, histoclinical parameters and selected protein products of cell-cycle regulatory genes. J Exp Clin Cancer Res (2005) 0.79
Cyclin E immunoexpression in gastric cancer does not correlate with clinicopathological parameters. Histopathology (2003) 0.77
Role of cyclin E and p53 expression in progression of early gastric cancer. Gastric Cancer (1998) 0.76
Prognostic significance of immunohistochemical expression of p53 and retinoblastoma gene protein (pRB) in curatively resected gastric cancer. Korean J Intern Med (2005) 0.76
The loss of p27 protein has an independent prognostic significance in gastric cancer. Anticancer Res (2000) 0.75
The beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein E-deficient mice : dabigatran etexilate and atherosclerosis. Cardiovasc Drugs Ther (2012) 2.22
Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol (2005) 1.28
TGF-beta signalling in colon carcinogenesis. Cancer Lett (2011) 1.26
DNA repair systems as targets of cadmium toxicity. Toxicol Appl Pharmacol (2006) 1.21
MCM proteins as diagnostic and prognostic tumor markers in the clinical setting. Histol Histopathol (2010) 1.12
Amyand's hernia: a case report. World J Gastroenterol (2006) 1.11
Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis (2008) 1.07
Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Fundam Clin Pharmacol (2007) 1.03
Cyto-histological correlations in primary, recurrent and metastatic rhabdomyosarcoma: the institut Curie's experience. Diagn Cytopathol (2007) 1.02
FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis (2012) 1.01
Insights on augmenter of liver regeneration cloning and function. World J Gastroenterol (2006) 1.01
Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma. Pathol Oncol Res (2009) 1.00
Primary hydatid disease of the gallbladder: a rare clinical entity. J Hepatobiliary Pancreat Surg (2004) 1.00
Nonmelanoma skin cancer after renal transplantation: a single-center experience in 1736 transplantations. Int J Dermatol (2011) 1.00
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis. Pharmacol Res (2009) 0.98
Local and systemic toxicity of nanoscale debris particles in total hip arthroplasty. J Appl Toxicol (2012) 0.97
Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity. Dig Dis Sci (2008) 0.97
An extended retroperitoneal abscess caused by duodenal diverticulum perforation: report of a case and short review of the literature. Am Surg (2007) 0.97
Clinical considerations of primary hydatid disease of the pancreas. Pancreatology (2005) 0.96
Zinc and the liver: an active interaction. Dig Dis Sci (2007) 0.95
Primary melanoma of the gallbladder: does it exist? Report of a case and review of the literature. World J Gastroenterol (2006) 0.95
MAPKs and NF-κB differentially regulate cytokine expression in the diaphragm in response to resistive breathing: the role of oxidative stress. Am J Physiol Regul Integr Comp Physiol (2011) 0.93
The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: a retrospective follow-up study. Am J Kidney Dis (2006) 0.93
Gracilis myocutaneous flap: evaluation of potential risk factors and long-term donor-site morbidity. Microsurgery (2011) 0.92
The interleukin-6-174 promoter polymorphism is associated with a risk of development of Kaposi's sarcoma in renal transplant recipients. Anticancer Res (2004) 0.92
Perforation of a solitary diverticulum of sigmoid colon in an incarcerated scrotal hernia. Dig Dis Sci (2004) 0.92
Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival. Med Sci Monit (2009) 0.92
1H NMR-based metabonomics approach in a rat model of acute liver injury and regeneration induced by CCl4 administration. Toxicology (2012) 0.91
Clinical implication of plasma neutrophil gelatinase-associated lipocalin (NGAL) concentrations in patients with advanced carotid atherosclerosis. Clin Chem Lab Med (2010) 0.91
Non-operative management of blunt abdominal trauma. Is it safe and feasible in a district general hospital? Scand J Trauma Resusc Emerg Med (2009) 0.91
Correlation of Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) and Retinoid X Receptor-alpha (RXR-alpha) expression with clinical risk factors in patients with advanced carotid atherosclerosis. Med Sci Monit (2011) 0.91
The impact of aerobic exercise training on novel adipokines, apelin and ghrelin, in patients with type 2 diabetes. Med Sci Monit (2012) 0.91
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury. Curr Mol Med (2008) 0.91
Alternative bi-pectoral muscle flaps for postoperative sternotomy mediastinitis. Ann Thorac Surg (2006) 0.91
An unusual synchronous ileosigmoid and ileoileal knotting: a case report. J Med Case Rep (2014) 0.90
Clinical significance of tumor-associated antigen RCAS1 expression in human pancreatic ductal adenocarcinoma. Dig Dis Sci (2008) 0.90
NF-κB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links. Expert Opin Ther Targets (2014) 0.89
Nonmelanoma skin tumors involving the craniofacial region: our 22 years of experience. J Craniofac Surg (2007) 0.89
Peroxisome proliferator-activated receptor-gamma ligands as investigational modulators of angiogenesis. Expert Opin Investig Drugs (2007) 0.89
Toll-like receptors in liver ischemia reperfusion injury: a novel target for therapeutic modulation? Expert Opin Ther Targets (2009) 0.89
MCM-2 and MCM-5 expression in gastric adenocarcinoma: clinical significance and comparison with Ki-67 proliferative marker. Dig Dis Sci (2010) 0.89
Investigation of the lipophilic behaviour of some thiazolidinediones. Relationships with PPAR-gamma activity. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.87
Predictive significance of preoperative serum VEGF-C and VEGF-D, independently and combined with Ca19-9, for the presence of malignancy and lymph node metastasis in patients with gastric cancer. J Surg Oncol (2010) 0.87
Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials? World J Gastroenterol (2013) 0.86
Prognostic significance of transforming growth factor beta (TGF-β) signaling axis molecules and E-cadherin in colorectal cancer. Tumour Biol (2012) 0.86
Current evidence on the anticancer potential of Chios mastic gum. Nutr Cancer (2011) 0.86
Peroxisome Proliferator-Activated Receptor-gamma Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer. PPAR Res (2008) 0.85
Current clinical status on the preventive effects of cranberry consumption against urinary tract infections. Nutr Res (2013) 0.85
Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance? World J Gastroenterol (2008) 0.85
The role of matrix metalloproteinases in the pathophysiology and progression of human nervous system malignancies: a chance for the development of targeted therapeutic approaches? Expert Opin Ther Targets (2008) 0.85
Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions. Tumour Biol (2013) 0.85
Expression of DNA repair proteins, MSH2, MLH1 and MGMT in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients' survival. J Oral Pathol Med (2010) 0.84
Current evidence for histone deacetylase inhibitors in pancreatic cancer. World J Gastroenterol (2013) 0.84
Multi-targeted molecular therapeutic approach in aggressive neuroblastoma: the effect of Focal Adhesion Kinase-Src-Paxillin system. Expert Opin Ther Targets (2014) 0.84
Rat epigastric flap survival and VEGF expression after local copper application. Plast Reconstr Surg (2007) 0.84
Quantitative structure-activity relationship (QSAR) methodology in forensic toxicology: modeling postmortem redistribution of structurally diverse drugs using multivariate statistics. Forensic Sci Int (2009) 0.84
Clinical significance of HuR expression in human malignancy. Med Oncol (2014) 0.84
Ghrelin, another factor affecting bone metabolism. Med Sci Monit (2010) 0.84
Serum tissue inhibitor of metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) levels in colorectal cancer patients: associations with clinicopathological variables and patient survival. Int J Biol Markers (2010) 0.83
Prognostic and predictive value of thymidylate synthase expression in colon cancer. Dig Dis Sci (2007) 0.83
The role of peroxisome proliferator-activated receptor-γ in breast cancer. Anticancer Agents Med Chem (2012) 0.83
Pregnane X receptor (PXR) at the crossroads of human metabolism and disease. Curr Drug Metab (2013) 0.83
Expression of peroxisome proliferator activated receptor-gamma (PPAR-γ) in human non-small cell lung carcinoma: correlation with clinicopathological parameters, proliferation and apoptosis related molecules and patients' survival. Pathol Oncol Res (2012) 0.83
Evaluation of FAK and Src expression in human benign and malignant thyroid lesions. Pathol Oncol Res (2010) 0.83
Primary liver tumors: origin and target therapy. Expert Opin Ther Targets (2009) 0.83
Management of the airway without the use of neuromuscular blocking agents: the use of remifentanil. Fundam Clin Pharmacol (2011) 0.82
Toll-like receptor 4 immunohistochemical expression is enhanced in macrophages of symptomatic carotid atherosclerotic plaques. Cerebrovasc Dis (2010) 0.82
Proteasome inhibitors: possible novel therapeutic strategy for ischemia-reperfusion injury? Expert Opin Investig Drugs (2013) 0.82
An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study. BMC Gastroenterol (2007) 0.82
Evaluation of coxsackievirus and adenovirus receptor expression in human benign and malignant thyroid lesions. APMIS (2010) 0.82
Expression of DNA repair proteins MSH2, MLH1 and MGMT in human benign and malignant thyroid lesions: an immunohistochemical study. Med Sci Monit (2011) 0.82
Diagnostic and prognostic utility of serum receptor-binding cancer antigen expressed on SiSo cells (RCAS1) levels in colon cancer patients. Int J Biol Markers (2009) 0.82
Cyclin D1 and Rb protein expression and their correlation with prognosis in patients with colon cancer. World J Surg Oncol (2006) 0.82
Evaluation of the effects of laparotomy and laparoscopy on the immune system in intra-abdominal sepsis--a review. J Invest Surg (2009) 0.81
Experimentally modified Fontan circulation in an adolescent pig model without the use of cardiopulmonary bypass. Med Sci Monit (2011) 0.81
Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes. Acta Diabetol (2011) 0.81
Effects of fulminant hepatic encephalopathy on the adult rat brain antioxidant status and the activities of acetylcholinesterase, (Na(+),K (+))- and Mg (2+)-ATPase: comparison of the enzymes' response to in vitro treatment with ammonia. Metab Brain Dis (2008) 0.81
Involvement of hepatic stimulator substance in experimentally induced fibrosis and cirrhosis in the rat. Dig Dis Sci (2008) 0.81
Clinicopathological aspects of 18 Kaposi's sarcoma among 1055 Greek renal transplant recipients. Artif Organs (2004) 0.81
Anatomical landmarks: dimensions of the mastoid air cell system in the Mediterranean population. Our experience from the anatomy of 298 temporal bones. Anat Sci Int (2007) 0.81
Circadian variation in expression of G1 phase cyclins D1 and E and cyclin-dependent kinase inhibitors p16 and p21 in human bowel mucosa. World J Gastroenterol (2006) 0.81
Matrix metalloproteinases in the pathophysiology and progression of gynecological malignancies: could their inhibition be an effective therapeutic approach? Expert Opin Ther Targets (2009) 0.81
Peroxisome proliferator-activated receptor-γ in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Cancer Res Clin Oncol (2011) 0.81
Effects of short-term exposure to manganese on the adult rat brain antioxidant status and the activities of acetylcholinesterase, (Na,K)-ATPase and Mg-ATPase: modulation by L-cysteine. Basic Clin Pharmacol Toxicol (2008) 0.80
Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: an immunohistochemical study. Med Sci Monit (2011) 0.80
An epitome of DNA repair related genes and mechanisms in thyroid carcinoma. Cancer Lett (2009) 0.80
A rare case of myocardial infarction and ischemia in a cannabis-addicted patient. Clin Nucl Med (2007) 0.80
Farnesoid X Receptor (FXR) from normal to malignant state. Histol Histopathol (2012) 0.80
Effects of oral administration of (L)-arginine, (L)-NAME and allopurinol on intestinal ischemia/reperfusion injury in rats. Life Sci (2011) 0.80